Sanofi SA Announces Its Quadrivalent Vaccine against Meningoccocal Disease Menomune Has Been Prequalified by World Health Organization-DJ


Monday, 2 Sep 2013 08:00pm EDT 

Dow Jones reported that Sanofi SA said that one of its new quadrivalent vaccine against meningoccocal disease Menomune has been prequalified by the World Health Organization (WHO), for purchase by United Nations agencies. The purpose of the United Nations prequalification assessment is to provide assurance that candidate vaccines meet WHO recommendations on quality, safety and efficacy, including compliance with WHO's recommended standards for good manufacturing practice and good clinical practice. Menomune vaccine is designed for active immunization against invasive meningococcal disease caused by Neisseria meningitis serogroups A, C, Y, and W-135 for use in persons two years of age and older. 

Company Quote

74.99
-0.65 -0.86%
24 Dec 2014